JP2009517353A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517353A5
JP2009517353A5 JP2008541641A JP2008541641A JP2009517353A5 JP 2009517353 A5 JP2009517353 A5 JP 2009517353A5 JP 2008541641 A JP2008541641 A JP 2008541641A JP 2008541641 A JP2008541641 A JP 2008541641A JP 2009517353 A5 JP2009517353 A5 JP 2009517353A5
Authority
JP
Japan
Prior art keywords
crystalline form
compound
acid addition
addition salt
methanesulfonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008541641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517353A (ja
JP5844508B2 (ja
Filing date
Publication date
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Application filed filed Critical
Priority claimed from PCT/EP2006/011240 external-priority patent/WO2007059963A1/en
Publication of JP2009517353A publication Critical patent/JP2009517353A/ja
Publication of JP2009517353A5 publication Critical patent/JP2009517353A5/ja
Application granted granted Critical
Publication of JP5844508B2 publication Critical patent/JP5844508B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008541641A 2005-11-25 2006-11-23 メシル酸イマチニブのｆ結晶形 Expired - Fee Related JP5844508B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0524061.9 2005-11-25
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524062.7 2005-11-25
US74001605P 2005-11-28 2005-11-28
US74001805P 2005-11-28 2005-11-28
US74001705P 2005-11-28 2005-11-28
US60/740,016 2005-11-28
US60/740,017 2005-11-28
US60/740,018 2005-11-28
PCT/EP2006/011240 WO2007059963A1 (en) 2005-11-25 2006-11-23 F,g,h,i and k crystal forms of imatinib mesylate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014005741A Division JP2014074067A (ja) 2005-11-25 2014-01-16 メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形

Publications (3)

Publication Number Publication Date
JP2009517353A JP2009517353A (ja) 2009-04-30
JP2009517353A5 true JP2009517353A5 (enExample) 2010-01-14
JP5844508B2 JP5844508B2 (ja) 2016-01-20

Family

ID=37847165

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008541641A Expired - Fee Related JP5844508B2 (ja) 2005-11-25 2006-11-23 メシル酸イマチニブのｆ結晶形
JP2014005741A Pending JP2014074067A (ja) 2005-11-25 2014-01-16 メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014005741A Pending JP2014074067A (ja) 2005-11-25 2014-01-16 メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形

Country Status (13)

Country Link
US (6) US7893076B2 (enExample)
EP (3) EP1960380A1 (enExample)
JP (2) JP5844508B2 (enExample)
KR (4) KR20080078804A (enExample)
CN (1) CN102351842B (enExample)
AU (2) AU2006316823A1 (enExample)
BR (1) BRPI0618993A2 (enExample)
CA (3) CA2824307C (enExample)
EC (1) ECSP088473A (enExample)
MY (1) MY146403A (enExample)
NO (1) NO20082684L (enExample)
UY (1) UY29964A1 (enExample)
WO (1) WO2007059963A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
KR20080078804A (ko) * 2005-11-25 2008-08-28 노파르티스 아게 이마티니브 메실레이트의 ｆ, ｇ, ｈ, ｉ 및 ｋ 결정형
US8414918B2 (en) 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
RU2365587C1 (ru) * 2008-02-22 2009-08-27 Закрытое Акционерное Общество "Фарм-Синтез" Рентгеноаморфная безводная модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил]бензамида метансульфоната и способ ее получения
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
AU2011213936A1 (en) 2010-02-15 2012-09-06 Sharma Ashwani Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
US9221789B2 (en) 2012-06-22 2015-12-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
US10478290B2 (en) * 2013-11-26 2019-11-19 Children's Medical Center Corporation Expandable stent valve
WO2018089404A1 (en) 2016-11-11 2018-05-17 Mallinckrodt Nuclear Medicine Llc Processes for generating germanium-68 with reduced volatiles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
WO2004106326A1 (en) * 2003-06-02 2004-12-09 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
US8048883B2 (en) * 2004-02-11 2011-11-01 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
CN102085202A (zh) 2004-06-04 2011-06-08 比奥尼斯生命科学公司 伊马替尼在治疗肝脏疾病和病毒感染中的用途
TR200701870T1 (tr) * 2004-09-02 2007-05-21 Cipla Limited İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
AR055613A1 (es) * 2005-08-26 2007-08-29 Novartis Ag Formas cristalinas delta y epsilon de mesilato de imatinib
KR20080078804A (ko) * 2005-11-25 2008-08-28 노파르티스 아게 이마티니브 메실레이트의 ｆ, ｇ, ｈ, ｉ 및 ｋ 결정형

Similar Documents

Publication Publication Date Title
JP2009506014A5 (enExample)
JP2009517353A5 (enExample)
JP2022176961A (ja) ｛［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
AU2006283842B2 (en) Delta and epsilon crystal forms of imatinib mesylate
JP2019528276A5 (enExample)
US8592440B2 (en) Crystalline form I of imatinib mesylate
JP2012512885A5 (enExample)
JP2013541592A5 (enExample)
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
CN103221411A (zh) (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
JP2010540440A5 (enExample)
JP5819705B2 (ja) イソキノリン誘導体塩酸塩無水物結晶
CN105377854B (zh) 纳美芬盐作为用于减少酒精消费或用于防止过度酒精消费的药剂
RU2008125299A (ru) Кристаллические f-, g-, h-, i- и к-формы иматинибмезилата
HK1177737A (en) Crystal form h of imatinib mesylate
CN101312960A (zh) 甲磺酸伊马替尼的f、g、h、i和k晶形
MX2008006696A (en) F,g,h,i and k crystal forms of imatinib mesylate